Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
©2024 American Association for Cancer Research..
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including KRAS-mutant non-small cell lung cancer (NSCLC). However, the clinical efficacy of CDK4/6 inhibitors is limited due to frequent drug resistance and their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred resistance to the CDK4/6 inhibitor palbociclib in KRAS-mutant NSCLC cells. Inhibition of BRD4, either by RNA interference or small-molecule inhibitors, synergized with palbociclib to induce senescence in NSCLC cells and tumors, and the combination prolonged survival in a KRAS-mutant NSCLC mouse model. Mechanistically, BRD4-inhibition enhanced cell-cycle arrest and reactive oxygen species (ROS) accumulation, both of which are necessary for senescence induction; this in turn elevated GPX4, a peroxidase that suppresses ROS-triggered ferroptosis. Consequently, GPX4 inhibitor treatment selectively induced ferroptotic cell death in the senescent cancer cells, resulting in tumor regression. Cotargeting CDK4/6 and BRD4 also promoted senescence and ferroptosis vulnerability in pancreatic and breast cancer cells. Together, these findings reveal therapeutic vulnerabilities and effective combinations to enhance the clinical utility of CDK4/6 inhibitors.
SIGNIFICANCE: The combination of cytostatic CDK4/6 and BRD4 inhibitors induces senescent cancer cells that are primed for activation of ferroptotic cell death by targeting GPX4, providing an effective strategy for treating cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Cancer research - 84(2024), 8 vom: 15. Apr., Seite 1333-1351 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Xianbing [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-23-1749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367675560 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367675560 | ||
| 003 | DE-627 | ||
| 005 | 20240416232459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-23-1749 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM367675560 | ||
| 035 | |a (NLM)38277141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Xianbing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2024 American Association for Cancer Research. | ||
| 520 | |a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for breast cancer treatment and show activity against other malignancies, including KRAS-mutant non-small cell lung cancer (NSCLC). However, the clinical efficacy of CDK4/6 inhibitors is limited due to frequent drug resistance and their largely cytostatic effects. Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred resistance to the CDK4/6 inhibitor palbociclib in KRAS-mutant NSCLC cells. Inhibition of BRD4, either by RNA interference or small-molecule inhibitors, synergized with palbociclib to induce senescence in NSCLC cells and tumors, and the combination prolonged survival in a KRAS-mutant NSCLC mouse model. Mechanistically, BRD4-inhibition enhanced cell-cycle arrest and reactive oxygen species (ROS) accumulation, both of which are necessary for senescence induction; this in turn elevated GPX4, a peroxidase that suppresses ROS-triggered ferroptosis. Consequently, GPX4 inhibitor treatment selectively induced ferroptotic cell death in the senescent cancer cells, resulting in tumor regression. Cotargeting CDK4/6 and BRD4 also promoted senescence and ferroptosis vulnerability in pancreatic and breast cancer cells. Together, these findings reveal therapeutic vulnerabilities and effective combinations to enhance the clinical utility of CDK4/6 inhibitors | ||
| 520 | |a SIGNIFICANCE: The combination of cytostatic CDK4/6 and BRD4 inhibitors induces senescent cancer cells that are primed for activation of ferroptotic cell death by targeting GPX4, providing an effective strategy for treating cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cyclin-Dependent Kinase 4 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Cytostatic Agents |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 6 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Fu, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Dutchak, Kendall |e verfasserin |4 aut | |
| 700 | 1 | |a Arabzadeh, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Milette, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Steinberger, Jutta |e verfasserin |4 aut | |
| 700 | 1 | |a Morin, Geneviève |e verfasserin |4 aut | |
| 700 | 1 | |a Monast, Anie |e verfasserin |4 aut | |
| 700 | 1 | |a Pilon, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Bianca N |e verfasserin |4 aut | |
| 700 | 1 | |a Prando Munhoz, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Hosein, Hannah J B |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Tianxu |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Yibo |e verfasserin |4 aut | |
| 700 | 1 | |a Rayes, Roni |e verfasserin |4 aut | |
| 700 | 1 | |a Sangwan, Veena |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Logan A |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guojun |e verfasserin |4 aut | |
| 700 | 1 | |a Quail, Daniela F |e verfasserin |4 aut | |
| 700 | 1 | |a Spicer, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Morag |e verfasserin |4 aut | |
| 700 | 1 | |a Dankort, David |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Sidong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 84(2024), 8 vom: 15. Apr., Seite 1333-1351 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2024 |g number:8 |g day:15 |g month:04 |g pages:1333-1351 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-23-1749 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2024 |e 8 |b 15 |c 04 |h 1333-1351 | ||